Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics.

Pharmacogenomics - 1 Sept 2008

Thelma Bk, Srivastava Vibhuti, Tiwari Arun Kumar

Abstract excerpt

Manifestation of tardive dyskinesia (TD) among schizophrenia subjects on long-term antipsychotic treatment with typical drugs has been a clinical concern. Despite its association with extrapyramidal symptoms, typical drugs are still routinely prescribed globally though marginally superior atypical drugs have long been available. The genetic component in the etiology of TD is well documented. Search for these...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Dyskinesia, Drug-Induced
Share to DRD3 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Predisposition to Disease

Share to Genetic Variation

Share to Pharmacogenetics

Share to Polymorphism, Genetic

Share to Schizophrenia

Source

Identifiers

PMID: 18781856
DOI: 10.2217/14622416.9.9.1285

Genes

DRD2
DRD3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics.PMID 18781856Read ↗

Pharmacogenetics of tardive dyskinesia: an updated review of the literature.Semantic proximity Read ↗

Genetics of tardive dyskinesia.Semantic proximity Read ↗

Genetic Factors Associated With Tardive Dyskinesia: From Pre-clinical Models to Clinical StudiesSemantic proximity Read ↗

Genetics of tardive dyskinesia: a review of progress over the past decade.Semantic proximity Read ↗

Epidemiology and risk factors for (tardive) dyskinesia.Semantic proximity Read ↗

Pharmacogenetic assessment of antipsychotic-induced movement disorders: contribution of the dopamine D3 receptor and cytochrome P450 1A2 genes.Semantic proximity Read ↗

Tardive Dyskinesia Development, Superoxide Dismutase Levels, and Relevant Genetic PolymorphismsSemantic proximity Read ↗

Genetics of Common Antipsychotic-Induced Adverse EffectsSemantic proximity Read ↗

Pharmacogenetics-Guided Advances in Antipsychotic Treatment.Semantic proximity Read ↗

Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms.Semantic proximity Read ↗

Pharmacogenetics of antipsychotic-induced side effects.Semantic proximity Read ↗

Pharmacogenetics of antipsychotic therapy: pivotal research issues and the prospects for clinical implementation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.